Skip to content
Safety & Legitimacy semaglutide

What Does the FDA Say About Compounded Semaglutide?

Last updated: January 2026

Quick Answer

The FDA allowed compounding during the semaglutide shortage (2023-2024). In 2025, after declaring the shortage resolved, the FDA moved to restrict compounding. Legal challenges from compounding pharmacies have kept access open in many states. Status continues to evolve.

What Does the FDA Say About Compounded Semaglutide

The FDA allowed compounding during the semaglutide shortage (2023-2024). In 2025, after declaring the shortage resolved, the FDA moved to restrict compounding. Legal challenges from compounding pharmacies have kept access open in many states. Status continues to evolve.

Safety is the most important consideration when starting any medication. GLP-1 medications have been extensively studied in clinical trials involving tens of thousands of patients, and they have a well-established safety profile when prescribed and monitored by licensed healthcare providers.

What the Research Shows

The STEP and SURMOUNT clinical trial programs included over 25,000 participants combined. These large-scale studies established the efficacy and safety profile that led to FDA approval for weight management.

Staying Safe on GLP-1 Treatment

  • Only obtain GLP-1 medications through licensed healthcare providers and pharmacies
  • Follow your prescribed dosing schedule and titration plan
  • Report any unusual symptoms to your provider promptly
  • Attend regular follow-up appointments for monitoring
  • Inform all your healthcare providers that you take GLP-1 medications
  • Keep medications stored properly and check expiration dates

Learn more about this medication: Semaglutide Complete Guide

Related Questions

More Safety & Legitimacy Questions